{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:04:48Z","timestamp":1767182688757,"version":"build-2238731810"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T00:00:00Z","timestamp":1463616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0155406","type":"journal-article","created":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T00:15:46Z","timestamp":1463703346000},"page":"e0155406","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["An Indirect Comparison of Efficacy and Safety of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Disoproxil Fumarate and Abacavir\/Lamivudine + Dolutegravir in Initial Therapy"],"prefix":"10.1371","volume":"11","author":[{"given":"Josep","family":"M. Llibre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Moyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Bouee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Piontkowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Rogatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,5,19]]},"reference":[{"key":"ref1","article-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/135965350100600207","article-title":"Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine\/zidovudine treatment","volume":"6","author":"W Rozenbaum","year":"2001","journal-title":"Antivir Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1468-1293.2003.00139.x","article-title":"TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks eff icacy, safety and adherence results","volume":"4","author":"C Katlama","year":"2003","journal-title":"HIV Med"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel","volume":"312","author":"HF G\u00fcnthard","year":"2014","journal-title":"JAMA"},{"key":"ref5","unstructured":"European AIDS Clinical Society guidelines, version 7.1\u2014November 2014.: European AIDS Clinical Society (<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eacsociety.org\/files\/guidelines_english_71_141204.pdf\" xlink:type=\"simple\">http:\/\/www.eacsociety.org\/files\/guidelines_english_71_141204.pdf<\/ext-link>)"},{"issue":"19","key":"ref6","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"SL Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"9868","key":"ref7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"F Raffi","year":"2013","journal-title":"Lancet"},{"key":"ref8","unstructured":"Clotet B, Khuong MA, Antinori A, Van Lunzen J, Dumitru I, Pokrovski V, et al. Once-daily dolutegravir versus darunavir\/ritanavir in antiretroviral naive adults: 48 week subgroup analyses from FLAMINGO. 14th European AIDS Conference; October 16\u201319; Brussels, Belgium."},{"issue":"9835","key":"ref9","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomized, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"PE Sax","year":"2012","journal-title":"Lancet"},{"issue":"9835","key":"ref10","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"E DeJesus","year":"2012","journal-title":"Lancet"},{"key":"ref11","unstructured":"Wohl D, Pozniak A, Thompson M, DeJesus E, Podzamcer D, Molina JM, et al. Tenofovir alafenamibe in a single-tablet regimen in initial HIV-1 therapy. CROI February 23\u201326 2015 Seattle. Abstract number 113LB."},{"key":"ref12"},{"key":"ref13"},{"key":"ref14","unstructured":"Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis (2009) by G. A. Wells, S. A. Sultan, L. Chen, M. Khan, D. Coyle edited by CADTH Canadian Agency for Drugs and Technologies in Health."},{"key":"ref15"},{"key":"ref16","unstructured":"Walmsley S, Berenguer J, Khuong-Josses, Kilby JM, Lutz T, Podzamczer D, et al. Dolutegravir regimen statistically superior to Efavirenz \/ Tenofovir \/ Emtricitabine: 96-week results from the single study (ING114467). Poster presented at the 21st conference on retroviruses and opportunistic infections; March 3\u20136, 2014, Boston."},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief Report: Dolutegravir Plus Abacavir\/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial","volume":"70","author":"S Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref18","unstructured":"Pappa K, Baumgarten A, Felizarta F, et al. Dolutegravir + abacavir\/lamivudine once daily superior to tenofovir\/emtricitabine\/efavirenz in treatment naive HIV subjects: 144-week results from SINGLE (ING114467). ICAAC 2014. September 5\u20139, 2014. Washington, DC."},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0b013e318289545c","article-title":"A randomized double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results","volume":"63","author":"A Zolopa","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref20","unstructured":"Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, et al. elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF (STB) has durable efficacy and differentiated long-term safety and tolerability versus efavirenz\/emtricitabine\/tenofovir DF (ATR) at week 144 in treatment na\u00efveHIV patients. Poster number H-672a at the 53rd Interscience Congress on Antimicrobial Agents therapy (ICAAC) September 10\u201313, 201 Denver, CO, USA."},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/QAI.0000000000000057","article-title":"A randomized, double-blind comparison of single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus single-tablet regimen efavirenz\/emtricitabine\/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results","volume":"65","author":"DA Wohl","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref22","unstructured":"Cohen C, Wohl DA, Gallant JE, Mills A, Sax PE, Dejesus E, et al. Elvitagravir\/cobicistat\/emtricitabine\/tenofovir DF (STB) has durable efficacy and differenciated long term safety and tolerability versus efavirenz\/emtricitabine\/tenofovir DF (ATR) at week 144 in treatment na\u00efve HIV patients. Poster PE7\/13 presented at the 14th European AIDS conference 16\u201319 October 2013 Brussels, Belgium."},{"key":"ref23","unstructured":"White K, Kulkarni R, Rhee1 MS, Fordyce MW, Miller MD. Longitudinal resistance analyses of the phase 3 EVG\/COBI\/FTC\/TDF studies. European Meeting on HIV &amp; Hepatitis Treatment Strategies &amp; Antiviral Drug Resistance March 26\u201328, 2014, Barcelona, Spain"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"HC Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"ref25","article-title":"HTA\u2014Indirect evidence: indirect treatment comparisons in meta-analysis","year":"2009","journal-title":"Canadian Agency for drugs and technologies in health"},{"key":"ref26","unstructured":"Indirect comparisons\u2014Methods and Validity. Rapport de synth\u00e8se\u2014Jully 2009. HAS available on the site: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2011-02\/summary_report__indirect_comparisons_methods_and_validity_january_2011_2.pdf\" xlink:type=\"simple\">http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2011-02\/summary_report__indirect_comparisons_methods_and_validity_january_2011_2.pdf<\/ext-link>. Accessed 2015 January 29th."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"S Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"ref28","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf\" xlink:type=\"simple\">http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf<\/ext-link>. Section accessed [April 23rd 2015.]"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"e105653","DOI":"10.1371\/journal.pone.0105653","article-title":"48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Na\u00efve HIV-1Infected Patients: A Systematic Review and Network Meta-Analysis","volume":"9","author":"DA Patel","year":"2014","journal-title":"PLoS One"},{"key":"ref30","unstructured":"U.S. Department of Health and Human Services (2013) Guidance for Industry: Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM355128.pdf\" xlink:type=\"simple\">http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM355128.pdf<\/ext-link>. Accessed 2015 January 29th."},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/01.aids.0000237369.41617.0f","article-title":"Tri-Service AIDS Clinical Consortium Natural History Study Group. Effectiveness of highly-active antiretroviral therapy by race\/ethnicity","volume":"20","author":"MJ Silverberg","year":"2006","journal-title":"AIDS"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0159286","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T00:00:00Z","timestamp":1467936000000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0155406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T16:21:32Z","timestamp":1656433292000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0155406"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,19]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0155406","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,19]]}}}